Solvias builds analytical testing center in the U.S.

08 May 2024 08:54

Supporting partner

Kaiseraugst - Solvias is expanding its analytical service capabilities with a new biotech site in the U.S. state of North Carolina. The North American hub will house a testing center for cell and gene therapies and biologics, supporting companies with advanced treatments for cancer and rare diseases.

Solvias, a biotech company based in Kaiseraugst in the canton of Aargau, is building a new biotech site to support life science organizations. According to a press release, this will enable the company to expand its analytical testing services to meet the growing demand for cell and gene therapies (CGTs) and biologics. The planned facility, which is scheduled to be built in 2025, will measure around 4,600 square meters and will create over 170 new jobs in the Raleigh-Durham region.

The North American hub will specialize in large molecule analytical services for the life science industry. It is the second U.S. location where the company will support life science companies with the latest analytical instruments. “Our new center strongly complements our biologics and CGT sites in Europe,” says Archie Cullen, CEO of Solvias. He adds the the team is delighted to bring their latest center of excellence to Research Triangle Park and to support customers in developing and maintaining life-changing therapies. ce/eb

Supporting partner

Swiss Pavilion Digital

Previous newsletters